GGrantIndex
← Leaderboards

Mark S Sands

Washington University

Google Scholar ↗PubMed ↗ORCID ↗
$13,206,849
Attributed
$13,206,849
Total exposure
11
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.2M · FY2005–22
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$13,206,849 · 11

By mechanism

R01$10,538,846 · 7
P30$1,140,975 · 1
P01$714,338 · 1
R21$429,875 · 1
R56$382,815 · 1

Top collaborators

No co-investigators on record.

Most similar at Washington University

Same institution · by research overlap

Others in their field

Top investigators on “Gene Therapy”

Research focus

Gene TherapyMediatingChildCessation Of LifeAffectSeizuresBiochemicalInheritedBrainNeurodegenerative DisordersResearch PersonnelBone Marrow TransplantationEnzymesDisease ProgressionFunctional DisorderChildhoodNeuronsCellsMotorPathogenesisCognitive DeficitsLongevityProteinsEffective Therapy

Grant awards (53)

Next Generation Treatment for Krabbe Disease$333,594
R01 · FY2022 · NS · contact PI
Next Generation Treatment for Krabbe Disease$333,594
R01 · FY2021 · NS · contact PI
Next Generation Treatment for Krabbe Disease$333,594
R01 · FY2020 · NS · contact PI
Next Generation Treatment for Krabbe Disease$333,594
R01 · FY2019 · NS · contact PI
Cannabidiol for the treatment of intractable seizures in infantile Batten disease$235,500
R21 · FY2019 · NS · contact PI
Next Generation Treatment for Krabbe Disease$333,594
R01 · FY2018 · NS · contact PI
Cannabidiol for the treatment of intractable seizures in infantile Batten disease$194,375
R21 · FY2018 · NS · contact PI
PATHOPHYSIOLOGY AND NOVEL THERAPIES FOR BATTEN'S DISEASE$323,589
R01 · FY2016 · NS · contact PI
PATHOPHYSIOLOGY AND NOVEL THERAPIES FOR BATTEN'S DISEASE$323,589
R01 · FY2015 · NS · contact PI
NOVEL THERAPIES FOR GLOBOID-CELL LEUKODYSTROPHY$376,200
R01 · FY2014 · NS · contact PI
PATHOPHYSIOLOGY AND NOVEL THERAPIES FOR BATTEN'S DISEASE$320,352
R01 · FY2014 · NS · contact PI
NOVEL THERAPIES FOR GLOBOID-CELL LEUKODYSTROPHY$49,925
R01 · FY2014 · NS · contact PI
NOVEL THERAPIES FOR GLOBOID-CELL LEUKODYSTROPHY$380,000
R01 · FY2013 · NS · contact PI
PATHOPHYSIOLOGY AND NOVEL THERAPIES FOR BATTEN'S DISEASE$350,377
R01 · FY2013 · NS · contact PI
PATHOPHYSIOLOGY AND NOVEL THERAPIES FOR BATTEN'S DISEASE$382,815
R56 · FY2012 · NS · contact PI
Pathophysiology and Novel Therapies for Batten's Disease$315,042
R01 · FY2011 · NS · contact PI
Novel Therapies for Globoid-Cell Leukodystrophy$282,399
R01 · FY2011 · HD · contact PI
Pathophysiology and Novel Therapies for Batten's Disease$318,256
R01 · FY2010 · NS · contact PI
Novel Therapies for Globoid-Cell Leukodystrophy$294,165
R01 · FY2010 · HD · contact PI
Washington University Center for Translational Neuroscience$227,456
P30 · FY2010 · NS · contact PI
Molecular scinces/viral vectors$134,873
P01 · FY2010 · NS · contact PI
Novel Therapies for Globoid-Cell Leukodystrophy$106,568
R01 · FY2010 · HD · contact PI
Pathophysiology and Novel Therapies for Batten's Disease$321,471
R01 · FY2009 · NS · contact PI
Novel Therapies for Globoid-Cell Leukodystrophy$297,136
R01 · FY2009 · HD · contact PI
Washington University Center for Translational Neuroscience$234,226
P30 · FY2009 · NS · contact PI
Molecular scinces/viral vectors$135,784
P01 · FY2009 · NS · contact PI
Pathophysiology and Novel Therapies for Batten's Disease$321,471
R01 · FY2008 · NS · contact PI
Novel Therapies for Globoid-Cell Leukodystrophy$297,890
R01 · FY2008 · HD · contact PI
Washington University Center for Translational Neuroscience$210,139
P30 · FY2008 · NS · contact PI
Molecular scinces/viral vectors$136,343
P01 · FY2008 · NS · contact PI
Pathophysiology and Novel Therapies for Batten's Disease$344,221
R01 · FY2007 · NS · contact PI
Novel Therapies for Globoid-Cell Leukodystrophy$313,855
R01 · FY2007 · HD · contact PI
Washington University Center for Translational Neuroscience$239,025
P30 · FY2007 · NS · contact PI
Molecular scinces/viral vectors$171,323
P01 · FY2007 · NS · contact PI
Novel Therapies for Lysosomal Storage Diseases$129,996
R01 · FY2007 · DK · contact PI
Pathophysiology and Novel Therapies for Batten's Disease$259,285
R01 · FY2006 · NS · contact PI
Washington University Center for Translational Neuroscience$230,129
P30 · FY2006 · NS · contact PI
Molecular scinces/viral vectors$136,015
P01 · FY2006 · NS · contact PI
Novel Therapies for Lysosomal Storage Diseases$133,878
R01 · FY2006 · DK · contact PI
Pathophysiology and Novel Therapies for Batten's Disease$268,043
R01 · FY2005 · NS
Novel Therapies for Lysosomal Storage Diseases$142,400
R01 · FY2005 · DK
Pathophysiology and Novel Therapies for Batten's Disease$270,560
R01 · FY2004 · NS
Novel Neuronal Transport Mechanisms of Lyosomal Enzymes$248,140
R01 · FY2004 · HD
NOVEL THERAPIES FOR LYSOSOMAL STORAGE DISEASES$237,843
R01 · FY2004 · DK
Pathophysiology and Novel Therapies for Batten's Disease$283,148
R01 · FY2003 · NS
Novel Neuronal Transport Mechanisms of Lyosomal Enzymes$248,140
R01 · FY2003 · HD
NOVEL THERAPIES FOR LYSOSOMAL STORAGE DISEASES$241,150
R01 · FY2003 · DK
Novel Neuronal Transport Mechanisms of Lyosomal Enzymes$261,390
R01 · FY2002 · HD
NOVEL THERAPIES FOR LYSOSOMAL STORAGE DISEASES$242,095
R01 · FY2002 · DK
NOVEL THERAPIES FOR LYSOSOMAL STORAGE DISEASES$55,594
R01 · FY2002 · DK
NOVEL THERAPIES FOR LYSOSOMAL STORAGE DISEASES$254,273
R01 · FY2001 · DK
NOVEL THERAPIES FOR LYSOSOMAL STORAGE DISEASES$51,010
R01 · FY2001 · DK
FUNCTIONAL STUDIES OF MPS VII MICE AFTER ENZYME THERAPY$207,425
R01 · FY2000 · HD